We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
51
argenx
ARGX
$63.8B
$10.1M 0.39%
450,000
– –
QURE icon
52
uniQure
QURE
$3.54B
$9.98M 0.38%
1,040,119
-50,000
-5% -$402K
ABMD
53
DELISTED
Abiomed Inc
ABMD
$8.72M 0.33%
+51,729
New +$7.82M
ATHN
54
DELISTED
Athenahealth, Inc.
ATHN
$8.71M 0.33%
+70,000
New +$9.64M
MRNS
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.53M 0.33%
+363,175
New +$4.07M
URGN icon
56
UroGen Pharma
URGN
$2.27B
$8.48M 0.32%
269,014
– –
OXFD
57
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.82M 0.3%
465,356
+421,250
+955% +$6.86M
ARDX icon
58
Ardelyx
ARDX
$976M
$7.57M 0.29%
1,352,391
-458,190
-25% -$2.41M
SNDA icon
59
Sonida Senior Living
SNDA
$1.97B
$7.03M 0.27%
37,345
+2,000
+6% +$393K
EXAS
60
DELISTED
Exact Sciences
EXAS
$6.38M 0.24%
135,444
+35,444
+35% +$1.43M
CMTA
61
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$6.29M 0.24%
+352,250
New +$5.76M
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.2M 0.24%
1,117,324
– –
ZYME icon
63
Zymeworks
ZYME
$1.96B
$5.83M 0.22%
730,768
– –
TLPH icon
64
Talphera
TLPH
$63.8M
$5.72M 0.22%
62,230
-124,337
-67% -$7.75M
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.67M 0.22%
91,380
– –
HRTX icon
66
Heron Therapeutics
HRTX
$61.3M
$5.33M 0.2%
+330,000
New +$5.18M
ICPT
67
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.22M 0.2%
+90,000
New +$9.69M
CLSD
68
DELISTED
Clearside Biomedical
CLSD
$5.15M 0.2%
41,345
– –
ZLAB icon
69
Zai Lab
ZLAB
$2.94B
$4.72M 0.18%
+175,000
New +$4.88M
OMED
70
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$4.69M 0.18%
+1,038,289
New +$4.21M
ARAV
71
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.63M 0.18%
314,693
-419,860
-57% -$42.4M
LUMO
72
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.58M 0.18%
+50,000
New +$3.83M
MMSI icon
73
Merit Medical Systems
MMSI
$5.44B
$4.24M 0.16%
+100,000
New +$4.03M
MTEM
74
DELISTED
Molecular Templates, Inc.
MTEM
$4.23M 0.16%
+48,276
New +$4.17M
NEPT
75
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$4.11M 0.16%
4,657
– –
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.